| |
HLA 10/10
|
HLA 9/10
|
HLA 8/10
|
p value
|
|---|
|
Total number of patients
|
2567
|
723
|
108
| |
|---|
|
Engraftment, n (%)
|
2458 (97.3 %)
|
678 (96.3 %)
|
101 (97.12 %)
|
0.313
|
|
No engraftment, n (%)
|
67 (2.7 %)
|
26 (3.7 %)
|
3 (2.9 %)
| |
|
Missing, n
|
42
|
19
|
5
| |
|
Median time ANC >0.5 G/L (days, range)
|
16 (0–103)
|
16 (1–165)
|
15.5 (1–33)
|
0.538
|
|
Acute GVHD,
| | | | |
|
Grade 0–I, n (%)
|
1826 (74.4 %)
|
469 (67.2 %)
|
67 (65.7 %)
|
0.0002
|
|
Grades II–IV, n (%)
|
629 (25.6 %)
|
229 (32.8 %)
|
35 (34.3 %)
| |
|
Grades III–IV, n (%)
|
234 (9.5 %)
|
90 (12.9 %)
|
11 (10.8 %)
|
0.035
|
|
Missing, n
|
75
|
21
|
3
| |
|
Chronic GVHDa
| | | | |
|
All grades
|
35.0 % [32.9–37.2]
|
35.1 % [31.2–39]
|
44.4 % [33.6–54.6]
|
0.138
|
|
Extensive
|
17.1 % [15.4–18.9]
|
15.2 % [12.3–18.5]
|
26.1 % [16.8–36.4]
|
0.047
|
|
Limited, n
|
369
|
109
|
14
| |
|
Extensive, n
|
324
|
80
|
21
| |
|
Missing, n
|
38
|
18
|
5
| |
-
GVHD graft-versus-host disease
-
aTwo-year cumulative incidence
